# Everest Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/everest-medicines

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.everestmedicines.com
- Total disclosed funding: $310M
- Latest round: Series C (May 29, 2020)
- Investors on record: 12

## About

Founded in 2017 and based in New York, US, Everest Medicines Ltd. operates as a biopharmaceutical company that develops drug candidates for oncology, immunology, cardio-renal disease, and infectious diseases. The company has raised a total of USD 310 millions of venture funding rounds. In October 2020, the company was listed on the Hong Kong stock exchange under the stock code 1952.HK.

The company's clinical and regulatory teams focus on licensing, developing, and commercializing innovative clinical-stage drug candidates, including Trodelvy, FGF401, Etrasimod, Nefecon, Xerava, VNRX-5133, and SPR206, a treatment for multi-drug resistant (MDR) Gram-negative bacterial infections.

Everest Medicines Ltd. agreed with Spero Therapeutics to develop, manufacture, and commercialize SPR206, a treatment for MDR (multi-drug resistant) bacterial infections, in greater China, South Korea, and certain Southeast Asian countries.

## Funding rounds

- Series C, May 29, 2020, $260M — HBM Partners, Janchor Partners, Hillhouse Investment, Decheng Capital, Pavilion Capital, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, CBC Group, China Reform Holdings, Janus Henderson Investors, Octagon Capital Advisors
- Series A, Feb 1, 2018, $50M — CBC Group

## Investors

- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series A, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Janchor Partners — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series C
- Pavilion Capital — Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series C
- Rock Springs Capital — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series C
- Janus Henderson Investors — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C